<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519957</url>
  </required_header>
  <id_info>
    <org_study_id>COMP004</org_study_id>
    <nct_id>NCT04519957</nct_id>
  </id_info>
  <brief_title>Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)</brief_title>
  <official_title>Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COMPASS Pathways</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>COMPASS Pathways</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the long-term efficacy of psilocybin with&#xD;
      respect to use of new antidepressant treatment, hospitalisations for depression, suicidality,&#xD;
      and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)&#xD;
      over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from&#xD;
      COMP 001).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this present study (COMP 004), the aim is to follow up participants from COMP 001 and COMP&#xD;
      003 in a long-term follow up study, with both remote and digital assessments, to explore the&#xD;
      long term efficacy and safety of the three different doses of psilocybin (1 mg, 10 mg, and 25&#xD;
      mg) administered to patients with TRD as a monotherapy in COMP 001 and 25 mg psilocybin&#xD;
      administered as an adjunct to an SSRI in COMP 003. Patients previously treated in COMP001&#xD;
      will be followed for approximately 40 weeks and patients previosuly treated in COMP003 will&#xD;
      be followed for approximately 49 weeks giving a total follow up period of 52 weeks from&#xD;
      psilocybin dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term efficacy of psilocybin</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response, sustained response, remission and change in depression severity</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Montgomery Asberg Depression Rating Scale (MADRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial functioning and to predict durability of response to antidepressant treatment</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Work and Social Adjustment Scale (WSAS) score change from Baseline of the prior study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional impairment in work/school, social life, and family life.</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Sheehan Disability Scale (SDS) score change from Baseline of the prior study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Psilocybin</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Incidence and severity of Adverse Events (AEs) and Seroius Adverse Events (SAEs)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <eligibility>
    <study_pop>
      <textblock>
        TRD patients who completed COMP001 or COMP003&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Signed ICF Each participant having completed the final study visit of either COMP 001 or&#xD;
        COMP 003 Ability to complete all protocol required assessment tools (including having&#xD;
        access to the internet in order to complete the digital assessments) without any assistance&#xD;
        or alteration to the copyrighted assessments, and to comply with all study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subject has any condition, for which in the opinion of the investigator, participation&#xD;
        would not be in the interest of the subject eg participation could compromise the wellbeing&#xD;
        of the participant or prevent, limit, or confound the protocol-specified assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sue Stansfield</last_name>
    <phone>+447780523013</phone>
    <email>sue@compasspathways.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kadima Neuropsychiatry Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Johnson</last_name>
      <email>olgaJ@kadimanp.com</email>
    </contact>
    <investigator>
      <last_name>David Feifel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Institute, University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Cardoso</last_name>
      <email>mailto:PsilocybinStudy@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Sidney Zisook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mood and Anxiety Disorders Program Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Mletzk</last_name>
      <phone>404-712-5063</phone>
      <email>tmletzk@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Boadie Dunlop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Center of Excellence on Mood Disorders, University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chung</last_name>
      <email>Daniel.Chung@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jair Soares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Mental Health Czech Republic</name>
      <address>
        <city>Klecany</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zusana Postranecka</last_name>
      <email>Zuzana.Postranecka@nudz.cz</email>
    </contact>
    <contact_backup>
      <last_name>Alice Heuschneiderova</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tomas Palenicek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheaf House, Tallaght Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Baker</last_name>
      <phone>00353867835422</phone>
      <email>abaker@clinicalresearchplatform.com</email>
    </contact>
    <investigator>
      <last_name>Veronica O'Keane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groningen University Medical Centre</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice Vischjager</last_name>
      <email>m.vischjager@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Schoevers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College London, Institute of Psychiatry, Psychology and Neurology</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Bird</last_name>
      <email>catherine.bird@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Allan Young</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

